https://www.airfinity.com/reports/covid-19-vaccine-revenue-forecast-2021-2022
We predict Pfizer BioNTech vaccines to earn $10.6
billion in Q3, with Moderna and Astrazeneca to follow with $6.1 and $1
billion. Pfizer and Moderna’s vaccines look set to dominate the market
next year due to the vaccines’ high efficacy and rapid scaling of
production. Airfinity’s modelling shows Pfizer BioNTech’s sales will
increase 77% in 2022, while Moderna’s will increase by 130% next year.
Pfizer, Moderna will rake in a combined $93 billion next year on COVID-19 vaccine sales: report
Aucun commentaire:
Enregistrer un commentaire